VP-005

VP-005 is a metal-based small molecule therapeutic candidate, specifically a gold complex, under development by Varsity Pharmaceuticals for the treatment of breast cancer. As a member of the gold-based drug class, VP-005 is designed to target cancer cells through mechanisms that potentially include the inhibition of thioredoxin reductase or the induction of mitochondrial-mediated apoptosis, though its specific molecular target has not been publicly disclosed. The compound is part of a pipeline focused on addressing resistant cancers and was slated to enter clinical evaluation in 2023 following preclinical studies.